IP Library Granted Patent US 12,144,802
Granted Patent B2
US 12,144,802 · App. 18/217,287 · Granted Nov 19, 2024

Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Inventors: David W. Osborne (Fort Collins, CO); Babak N. Tofig (Westlake Village, CA); Frank Watanabe (Westlake Village, CA)
Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
A61K31/44A61K9/0014A61K47/10A61K47/14A61K47/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,144,802
App. No.
18/217,287
Granted
Nov 19, 2024
Kind
B2
Abstract

Topical pharmaceutical compositions comprising roflumilast and solvents that are capable of dissolving high amounts of roflumilast. The pharmaceutical compositions are capable of dissolving high amounts of roflumilast relative to other commonly used solvents in approved topical pharmaceutical compositions. The solvents are particularly useful when combined with water to maintain high levels of dissolved roflumilast, which is highly insoluble in water.

Claims (20)

1. A topical pharmaceutical composition comprising a pharmaceutically effective amount of roflumilast, water, and a pharmaceutically acceptable solvent selected from the group consisting of 1,3-butylene glycol, 1,2-hexanediol, 1,3-propanediol, 1,2-pentanediol, dipropylene glycol, 2-(2-butoxy-ethoxy) ethanol, 1,6-hexanediol, propylene glycol methyl ethyl acetate, 5-methyloxolan-2-one, pantolactone, and combinations thereof.

2. The pharmaceutical composition of claim 1 , wherein said roflumilast is present in an amount of about 0.005% to about 2% w/w.

3. The pharmaceutical composition of claim 2 , wherein the solvent is present in an amount sufficient to maintain the stability of the pharmaceutical composition for 3 months after storage at controlled room temperature.

4. The pharmaceutical composition of claim 2 , wherein the solvent is in an amount sufficient to maintain at least 95% of the roflumilast dissolved for 3 months after storage at controlled room temperature.

5. The pharmaceutical composition of claim 2 , wherein the solvent is present in an amount sufficient to maintain the stability of the pharmaceutical composition for 3 months after storage at 40° C.

6. The pharmaceutical composition of claim 2 , wherein the solvent is in an amount sufficient to maintain at least 95% of the roflumilast dissolved for 3 months after storage at 40° C.

7. The pharmaceutical composition of claim 2 , wherein said solvent and water are present in an approximately equal molar blend.

8. The pharmaceutical composition of claim 2 , wherein said solvent and water are present in an approximately 1:2 solvent to water blend (weight:weight).

9. The pharmaceutical composition of claim 3 , wherein said pharmaceutical composition is selected from the group consisting of an emulsion, a gel, and an ointment.

10. The pharmaceutical composition of claim 9 , wherein said pharmaceutical composition further comprises at least one additional component selected from the group consisting of a moisturizer, a surfactant or emulsifier, a polymer or thickener, an antifoaming agent, a preservative, an antioxidant, a sequestering agent, a stabilizer, a buffer, a pH adjusting agent, a skin penetration enhancer, a film former, a dye, a pigment, and a fragrance.

11. The pharmaceutical composition of claim 3 , wherein the solvent comprises 1,3-butylene glycol.

12. The pharmaceutical composition of claim 3 , wherein the solvent comprises 1,2-hexanediol.

13. The pharmaceutical composition of claim 3 , wherein the solvent comprises 1,3-propanediol.

14. The pharmaceutical composition of claim 3 , wherein the solvent comprises 1,2-pentanediol.

15. The pharmaceutical composition of claim 3 , wherein the solvent comprises dipropylene glycol.

16. The pharmaceutical composition of claim 3 , wherein the solvent comprises 2-(2-butoxy-ethoxy) ethanol.

17. The pharmaceutical composition of claim 3 , wherein the solvent comprises 1,6-hexanediol.

18. The pharmaceutical composition of claim 3 , wherein the solvent comprises propylene glycol methyl ethyl acetate.

19. The pharmaceutical composition of claim 3 , wherein the solvent comprises 5-methyloxolan-2-one.

20. The pharmaceutical composition of claim 3 , wherein the solvent comprises pantolactone.

Assignments (2)
SECURITY INTEREST Recorded Aug 9, 2024
From: ARCUTIS BIOTHERAPEUTICS, INC.
To: SLR INVESTMENT CORP.
Reel/Frame 068236/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2023
From: OSBORNE, DAVID W.; TOFIG, BABAK N.; WATANABE, FRANK
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 065971/0974 →
Continuity (2)
Provisional Application 63406921 · Sep 15, 2022
Related Publication 20240108609A1 · Apr 4, 2024